Abstract 2388
Background
While hormone receptor-positive (HR+) and negative (HR-) HER2+ breast cancers (BC) are thought to be distinct diseases, only few studies have investigated the impact of HR status in the context of trastuzumab (TRZ)-treated BC. We evaluated the impact of HR status on outcomes of HER2+ early BC, before and after generalization of TRZ.
Methods
Patients were identified from a cohort of 23,374 women who underwent primary surgery in 18 centers between 2000 and 2017. Since the year 2005 marked the generalization of TRZ, we conducted distinct analyses in patients treated between 2000 and 2004 and those treated between 2005 and 2017. Impact of HR status analyses were done with censorship of events occurring after 5 years in both cohorts. Proportionality tests included all events.
Results
Of 970 HER2+ patients, 349 were treated between 2000 and 2004 without TRZ, and 621 between 2005 and 2017, with TRZ-based adjuvant chemotherapy. Endocrine therapy was received by 92 and 94% of HR+ patients, respectively. In the first group, HR status impacted disease-free survival (DFS) in univariate analysis (Hazard ratio: 2.44 [1.43-4.19]; p < 0.001, log-rank test). Conversely, HR status did not significantly impact DFS in the cohort with TRZ (1.34 [0.66-2.71], p = 0.414). Overall survival was also impacted by HR status in the group without TRZ (Hazard ratio: 2.49 [1.23-5.04]; p = 0.009), but not in the TRZ group (0.68 [0.23-2.00]; p = 0.482). These results were maintained in multivariate analysis including age, LVI, lymph node involvement, histology, grade and tumor size. Evolution of Hazard ratio over time for cumulative incidence of first recurrence according to HR status in patients without TRZ showed a non-proportionality of risks on metastatic (p = 0.027, AD-test) recurrences, with a decreasing risk for HR- over time. Conversely, the analysis of cumulative incidence of first recurrence did not show such a trend in patients treated with TRZ, suggesting the proportionality of the risks over time for HR status.
Conclusions
Instead patients treated without TRZ, HR status was no longer determinant of outcomes when patients received TRZ. These observations are supported by the analysis of Hazard ratio’s evolution over time for cumulative incidence of first metastatic recurrence.
Clinical trial identification
Legal entity responsible for the study
Gilles Houvenaeghel.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract